Evidence map›Paper›PMID 28801923›Full record

ArticleBiomedical chromatography : BMC2018

Sensitive liquid chromatography/tandem mass spectrometry method for the determination of two novel highly lipophilic anticancer drug candidates in rat plasma and tissues.

Shirin Hooshfar, Michael R Linzey, Daqing Wu, Lajos Gera, Kenza Mamouni, Xin Li, Yanhua Chen, Yang Yang, Oluwasegun Olorunyolemi, Michael G Bartlett

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedical chromatography : BMC, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shirin HooshfarDepartment of Pharmaceutical and Biomedical Sciences, College of Pharmacy, The University of Georgia, Athens, GA, USA.
Michael R LinzeyDepartment of Pharmaceutical and Biomedical Sciences, College of Pharmacy, The University of Georgia, Athens, GA, USA.
Daqing WuDepartment of Biochemistry and Molecular Biology, Augusta University, Augusta, GA, USA.
Lajos GeraDepartment of Biochemistry and Molecular Genetics, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
Kenza MamouniDepartment of Biochemistry and Molecular Biology, Augusta University, Augusta, GA, USA.
Xin LiDepartment of Biochemistry and Molecular Biology, Augusta University, Augusta, GA, USA.
Yanhua ChenDepartment of Biochemistry and Molecular Biology, Augusta University, Augusta, GA, USA.
Yang YangDepartment of Biochemistry and Molecular Biology, Augusta University, Augusta, GA, USA.
Oluwasegun OlorunyolemiDepartment of Pharmaceutical and Biomedical Sciences, College of Pharmacy, The University of Georgia, Athens, GA, USA.
Michael G BartlettDepartment of Pharmaceutical and Biomedical Sciences, College of Pharmacy, The University of Georgia, Athens, GA, USA.ORCID http://orcid.org/0000-0003-0626-3234

Funding

Targeting chemoresistant prostate cancer with novel EED inhibitorsR01CA256058 · NCI · CLARK ATLANTA UNIVERSITY · PI DAQING WU · 2022 to 2026
$2.1M
Novel small-molecule targeted therapy for prostate cancerR41CA206725 · NCI · METCURE THERAPEUTICS, LLC · PI WU, DAQING · 2016 to 2016
$225k
Small-molecule therapy for metastatic prostate cancerR41CA217491 · NCI · METCURE THERAPEUTICS, LLC · PI WU, DAQING · 2017 to 2017
$225k
A Dietary Supplement As Adjunct Therapy In Castration-Resistant Prostate CancerR41CA186498 · NCI · METCURE THERAPEUTICS, LLC · PI WU, DAQING · 2015 to 2015
$161k
NCI NIH HHS R01 CA256058NCI NIH HHS R41 CA186498NCI NIH HHS R41 CA206725NCI NIH HHS R41 CA217491
6 · The paper itself

Abstract

A simple and sensitive liquid chromatography/electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) method was developed and validated for determination of two highly lipophilic anticancer drug candidates, LG1980 and GH501, in rat plasma and tissues (liver, kidney and femur bones). LG1980 and GH501 were extracted from rat plasma and tissue homogenates using liquid-liquid extraction. The method provided a linear range of 1.0-200.0 ng/mL for GH501 in plasma and LG1980 in plasma and liver. For both analytes in other tissue homogenates the linear range was 2.0-400.0 ng/mL. The method was validated with precision within 15% relative standard deviation, accuracy within 15% relative error and a consistent recovery. This method has been successfully applied in two preclinical studies for LG1980 and GH501 to determine their concentrations in rat plasma, liver, kidney and bone over 24 h after intravenous injection of compounds.

Indexed as

AnimalsAntineoplastic AgentsChromatography, LiquidHydrophobic and Hydrophilic InteractionsKidneyLimit of DetectionLinear ModelsLiverMaleRatsRats, Sprague-DawleyReproducibility of ResultsTandem Mass SpectrometryTissue DistributionAntineoplastic Agentsbioanalysishighly lipophilic drugLC-MS/MSplasmatissue

Identifiers

PMID28801923
PMCPMC5786476

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.